RankAlpha logo

COAG

AI MemoPost-earnings T+1

Hemab Therapeutics

As of 2026-11-11/Post-earnings T+1/Confidence medium
Open tickerBack to Memos
Data freshness
AI Memo
As of 2026-11-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
—
Confidence
medium
Horizon
—
Key catalyst
Updated sutacimig Factor VII deficiency data at ASH • 2026-12-14
Base target: $37 / p=1% prob
Biggest risk
The wider quarterly loss and higher R&D spending accompany material trial and regulatory uncertainty, particularly SOLARA's design. The packet's negative directional prior and the post-print selloff argue against treating pipeline progress as an immediate bullish re-rating. A $65 LifeSci Capital target was reported on November 9, before earnings; no verified post-print target or estimate revision was found. Company release Pre-print analyst initiation
Invalidation
Break below $24 or thesis failure.
What would change my mind?
The move into Phase 3, two dated data presentations and $430.2 million in September 30 cash and marketable securities—with management projecting runway into 2029—support a multi-program opportunity. These are clinical-stage assets, not established commercial earnings. Company release
Research note
Recommendation
—
Confidence
medium
As of
2026-11-11
Base target
$37
p=1%
Bull target
$55
p=0%
Bear target
$24
p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Post-earnings reassessment
  • SOLARA Phase 3 execution and regulatory-design risk
  • The move into Phase 3, two dated data presentations and $430.2 million in September 30 cash and marketable securities—with management projecting runway into 2029—support a multi-program opportunity.
BearKey bullets
  • Initial Factor VII deficiency clinical data involve only two dosed participants, and earlier HMB-002 bleeding observations were descriptive rather than efficacy-tested.
  • Company release
  • No verified post-earnings analyst estimate or target revisions were available for this T+1 assessment.
WatchKey bullets
  • Updated sutacimig Factor VII deficiency data at ASH

Summary

High-level snapshot

Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+1
Base case: $37 (p=1%)
Target spread vs base: +49% / -35%
Scenario probabilities
Bull Target: $55 (p=0%)Base Target: $37 (p=1%)Bear Target: $24 (p=0%)
Commentary
The November 10 close was 9.44% below the prior close after an EPS miss and wider net loss, despite announced pipeline progress. This is an early T+1 reading: no verified post-print analyst revision, options, short-interest, employee or sufficiently covered social signal is available. The numerical sentiment fields without source coverage are unavailable rather than affirmative neutral readings. Earnings comparison and close Company release
As of 2026-11-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
The move into Phase 3, two dated data presentations and $430.2 million in September 30 cash and marketable securities—with management projecting runway into 2029—support a multi-program opportunity. These are clinical-stage assets, not established commercial earnings. Company release
Bear Case
The wider quarterly loss and higher R&D spending accompany material trial and regulatory uncertainty, particularly SOLARA's design. The packet's negative directional prior and the post-print selloff argue against treating pipeline progress as an immediate bullish re-rating. A $65 LifeSci Capital target was reported on November 9, before earnings; no verified post-print target or estimate revision was found. Company release Pre-print analyst initiation

Drivers

Scannable catalysts and supporting factors

  • Post-earnings reassessment
  • SOLARA Phase 3 execution and regulatory-design risk

Scenarios

Bull Target (Scenario probability)
$55 / p=0% prob
Base Target (Scenario probability)
$37 / p=1% prob
Bear Target (Scenario probability)
$24 / p=0% prob
Analysis 2026-11-11 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
-0.20
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-12-14
    Updated sutacimig Factor VII deficiency data at ASH
    Hemab expects to present updated Phase 2b data for dosed participants on December 14. Initial data covered only two participants: prothrombin time shortened by more than 50% in both, while approximately fivefold endogenous FVII(a) accumulation was observed in the participant with PK/PD data. Durability, safety and broader-patient consistency remain unproven. [#SEC-8K-2026-11-10] Company release
    Prob 85.00% • Move 8.00% • Priced-in 45.00%
  • EVENT2027-02-09
    HMB-002 VELORA Pioneer data at EAHAD
    Hemab expects additional Phase 1/2 Von Willebrand disease data in February 2027. Earlier pharmacodynamic results showed at least a 2.4-fold peak increase in VWF and FVIII, but the single-ascending-dose portion was not designed to measure efficacy; bleeding observations were descriptive. [#SEC-8K-2026-11-10] Company release
    Prob 75.00% • Move 10.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

  • Post-earnings reassessment
    2026-11-10
    Hemab reported a Q3 net loss of $27.3 million, or $0.58 per share, as R&D expense rose to $24.6 million from $14.6 million a year earlier. The reported EPS missed a $0.51-loss consensus estimate by $0.07, and shares closed November 10 at $38.77, down 9.44%. The operating figures are in the company release furnished with its 8-K; the consensus comparison and closing reaction are secondary-source figures. [#8-K-2026-11-10] [#SEC-8K-2026-11-10] Company release Earnings comparison and close
    Prob 100% • Move -9% • Priced-in 100%

Long-term Catalysts

Months to a year

  • SOLARA Phase 3 execution and regulatory-design risk
    2027-11-11
    Hemab initiated its approximately 75-participant pivotal sutacimig study in Glanzmann thrombasthenia. Enrollment and subsequent bleeding-rate evidence could reshape the thesis, but the FDA recommended considering a randomized controlled design; Hemab chose a single-arm, within-participant comparison. No pivotal readout date was established in the checked release. [#SEC-8K-2026-11-10] Company release
    Prob 65% • Move 15% • Priced-in 30%

Risks

  • Initial Factor VII deficiency clinical data involve only two dosed participants, and earlier HMB-002 bleeding observations were descriptive rather than efficacy-tested. Company release
  • No verified post-earnings analyst estimate or target revisions were available for this T+1 assessment.
  • Q3 R&D expense rose to $24.6 million; trial expansion could raise spending or shorten the projected runway. Company release
  • The FDA recommended that Hemab consider a randomized SOLARA design; regulators may require additional evidence despite the company's decision to proceed with a single-arm trial. Company release

Peers

No peer data

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-11-11